From a clinical perspective, it is noteworthy that patients with metastatic melanoma treated with the combination of anti-PD-1/high-dose IL-2 immunotherapy, who were also receiving concurrent administration of propranolol, experienced improved overall survival relative to those patients who did not receive β-blocker therapy [136]. This evidence concerns the gene IL2 and metastatic melanoma.